Dr. Richard Urso: Big Pharma Makes Billions by Rebranding Existing Drugs as ‘New’ Products
Video
American Thought Leaders
JAN JEKIELEK
“We have seen the ultimate demise of our health care system when it’s in the hands of bureaucrats,” says Dr. Richard Urso, a co-founder of the International Alliance of Physicians and Medical Scientists.
Previously, in part one of our interview, we discussed alarming post-booster trends he’s seen and how usual protocols for identifying treatments were thrown out during the COVID-19 pandemic.
Now in part two, we discuss how big pharmaceutical companies can make billions by essentially repackaging existing products.
“Basically they took almost the exact same drug as Kaletra, dressed it up, they put a box around it, and they’re selling it for what, [$]5 billion?” says Urso, referring to the Paxlovid COVID-19 pill.
We also discuss Urso’s work with other prominent doctors to create both a national telehealth system as well as an entirely new infrastructure of doctor-led medicine, where power is decentralized and less easily corrupted.
“Once doctors became employees during this pandemic, it made them very reluctant to speak out,” Urso says.
Urso is a drug design and treatment specialist, an ophthalmologist, and former chief of orbital oncology at MD Anderson Cancer Center.
Last edited:
